Hematology

Calibrating prognostic dialogue to support double awareness in hematologic malignancies

This qualitative study of 25 recorded serious-illness conversations describes how clinicians tailor prognostic depth and timing to patient and caregiver readiness. Preparatory materials and structured openings facilitated prognostic dialogue and supported patients' capacity for double awareness. Clinicians used prognostic uncertainty as a communicative resource rather than a barrier to discussion. Findings apply to hematologic malignancy patients, caregivers, and clinicians trained in serious-illness communication. 1

Incidence, risk factors, and outcomes of AIHA after allo‑HSCT

In a nested case-control cohort (61 cases), post-allo-HSCT autoimmune hemolytic anemia incidence was 0.72%. Unrelated donor increased AIHA risk (HR 2.323) while prior acute GVHD was protective (HR 0.340). Corticosteroids plus rituximab significantly improved response rates without observed treatment-related mortality. Age, LDH, and CRP were independent predictors of mortality; mononuclear cell dose correlated with AIHA relapse. 2

Real-world first-line AML treatments and outcomes in the United States

Among 2,516 newly diagnosed AML patients, cytarabine-based intensive chemotherapy remained the most used first-line regimen. Overall complete remission was 45%, highest with IC w/cytarabine (61%) and investigational therapies (62%). Use of HMA plus venetoclax increased after 2018 approval, with real-world outcomes similar to clinical trials. Survival differences favoring intensive cytarabine regimens are confounded by baseline patient selection. 3